J W Mier, F R Aronson, R P Numerof, G Vachino, M B Atkins
{"title":"白细胞介素-2和淋巴因子活化杀伤细胞免疫治疗的毒性。","authors":"J W Mier, F R Aronson, R P Numerof, G Vachino, M B Atkins","doi":"10.1159/000157075","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy with IL-2 represents a major breakthrough in the management of renal cell carcinoma and malignant melanoma. At present, the toxicity of most IL-2 regimens is severe and prohibitive for clinicians not intimately familiar with the myriad of side effects associated with its use. The elucidation of the mechanism by which the lymphokine induces tumor regression, the vascular leak syndrome and other side effects will permit IL-2 to be used more safely and effectively.</p>","PeriodicalId":77765,"journal":{"name":"Pathology and immunopathology research","volume":"7 6","pages":"459-76"},"PeriodicalIF":0.0000,"publicationDate":"1988-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000157075","citationCount":"56","resultStr":"{\"title\":\"Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.\",\"authors\":\"J W Mier, F R Aronson, R P Numerof, G Vachino, M B Atkins\",\"doi\":\"10.1159/000157075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Immunotherapy with IL-2 represents a major breakthrough in the management of renal cell carcinoma and malignant melanoma. At present, the toxicity of most IL-2 regimens is severe and prohibitive for clinicians not intimately familiar with the myriad of side effects associated with its use. The elucidation of the mechanism by which the lymphokine induces tumor regression, the vascular leak syndrome and other side effects will permit IL-2 to be used more safely and effectively.</p>\",\"PeriodicalId\":77765,\"journal\":{\"name\":\"Pathology and immunopathology research\",\"volume\":\"7 6\",\"pages\":\"459-76\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1988-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000157075\",\"citationCount\":\"56\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology and immunopathology research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000157075\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology and immunopathology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000157075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
Immunotherapy with IL-2 represents a major breakthrough in the management of renal cell carcinoma and malignant melanoma. At present, the toxicity of most IL-2 regimens is severe and prohibitive for clinicians not intimately familiar with the myriad of side effects associated with its use. The elucidation of the mechanism by which the lymphokine induces tumor regression, the vascular leak syndrome and other side effects will permit IL-2 to be used more safely and effectively.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
